Skip to main content
    M

    Myomo Inc (MYO)

    Official site

    HEALTHCARE • MEDICAL DEVICES • AMEX

    $1.03
    -0.20 (-16.26%)

    Market Cap: $49.32M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Myomo Inc (MYO) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Myomo (MYO) is confirmed to report earnings on Mar 8, 2027, after the close. In the quarter ended Sep 30, 2026, Myomo reported EPS of -$0.07, above the -$0.08 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    70%(26/37)
    Avg Surprise
    +13.16%
    Streak
    3 Q

    Upcoming Estimates

    Reports Mar 8, 2027 after closePeriod ending Dec 31, 2026
    EPS Consensus-$0.07
    Range-$0.08 - -$0.06
    6 analysts
    Revenue Consensus
    $12.32M
    Range$11.37M - $13.10M
    6 analysts
    Reports May 5, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.08
    Range-$0.10 - -$0.06
    3 analysts
    EPS Revisions
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.08-2.3%
    60d ago-$0.07-9.6%
    30d ago-$0.07-9.6%
    7d ago-$0.07-9.6%
    Current-$0.08
    Revenue Consensus
    $10.94M
    Range$9.50M - $11.71M
    4 analysts

    Next Report

    MYO has a confirmed report date of Mar 8, 2027, after the close.

    MYO Earnings Call

    The latest MYO earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 37 quarters below that had an estimate, MYO beat 26, missed 9 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $12.33M, up 22.2% from $10.09M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.07-$0.08-$0.08 - -$0.07+12.50%BeatN/A32 up, 1 downNov 9, 2026$12.33M
    Jun 30, 2026-$0.07-$0.10-$0.11 - -$0.09+30.00%BeatN/A30 up, 2 downAug 5, 2026$11.70M
    Mar 31, 2026-$0.09-$0.11-$0.13 - -$0.10+18.18%BeatN/A40 up, 3 downMay 7, 2026$10.11M
    Dec 31, 2025-$0.09-$0.08-$0.09 - -$0.08-1.43%MissN/A40 up, 4 downMar 9, 2026$11.35M
    Sep 30, 2025-$0.09-$0.11-$0.12 - -$0.10+18.18%BeatN/A50 up, 2 downNov 10, 2025$10.09M
    Jun 30, 2025-$0.11-$0.11-$0.12 - -$0.100.00%In lineN/A50 up, 5 downAug 11, 2025$9.65M
    Mar 31, 2025-$0.08-$0.08-$0.09 - -$0.060.00%In lineN/A51 up, 2 downMay 7, 2025$9.83M
    Dec 31, 2024-$0.01-$0.02-$0.04 - -$0.01+57.08%BeatN/A60 up, 1 downMar 10, 2025$12.07M
    Sep 30, 2024-$0.03-$0.04-$0.06 - -$0.03+25.00%BeatN/A60 up, 0 downNov 6, 2024$9.21M
    Jun 30, 2024-$0.03-$0.07-$0.09 - -$0.06+57.14%BeatN/A63 up, 0 downAug 6, 2024$7.52M
    Mar 31, 2024-$0.10-$0.09-$0.10 - -$0.09-11.11%MissN/A30 up, 0 downMay 8, 2024$3.75M
    Dec 31, 2023-$0.07-$0.06-$0.06 - -$0.05-16.67%MissN/A40 up, 0 downMar 7, 2024$4.76M
    Sep 30, 2023-$0.06-$0.09-$0.10 - -$0.08+33.33%BeatN/A40 up, 0 downNov 7, 2023$5.08M
    Jun 30, 2023-$0.04-$0.03-$0.05 - -$0.02-33.33%MissN/A40 up, 0 downAug 9, 2023$5.96M
    Mar 31, 2023-$0.11-$0.13-$0.15 - -$0.12+15.38%BeatN/A40 up, 0 downMay 10, 2023$3.45M
    Dec 31, 2022-$0.29-$0.42-$0.44 - -$0.38+30.95%BeatN/A40 up, 0 downMar 13, 2023$4.04M
    Sep 30, 2022-$0.40-$0.43-$0.53 - -$0.38+6.98%BeatN/A40 up, 0 downNov 10, 2022$3.97M
    Jun 30, 2022-$0.42-$0.43-$0.53 - -$0.37+2.33%BeatN/A40 up, 0 downAug 3, 2022$3.68M
    Mar 31, 2022-$0.41-$0.53-$0.60 - -$0.46+22.64%BeatN/A40 up, 0 downMay 11, 2022$3.87M
    Dec 31, 2021-$0.52-$0.49-$0.53 - -$0.44-6.12%MissN/A5N/AMar 9, 2022N/A
    Sep 30, 2021-$0.36-$0.46-$0.56 - -$0.41+21.74%BeatN/A54 up, 0 downNov 10, 2021$4.38M
    Jun 30, 2021-$0.46-$0.61-$0.70 - -$0.52+24.59%BeatN/A5N/AAug 9, 2021$3.10M
    Mar 31, 2021-$0.57-$0.68-$0.77 - -$0.58+16.18%BeatN/A4N/AMay 5, 2021$2.34M
    Dec 31, 2020-$0.37-$0.49-$0.56 - -$0.37+24.49%BeatN/A4N/AMar 10, 2021$3.79M
    Sep 30, 2020-$0.66-$1.05-$1.28 - -$0.83+37.14%BeatN/A4N/ANov 10, 2020$1.93M
    Jun 30, 2020-$1.02-$1.34-$1.36 - -$1.13+23.88%BeatN/A4N/AAug 10, 2020$858590
    Mar 31, 2020-$2.47-$2.32-$2.34 - -$1.54-6.47%MissN/A3N/AMay 14, 2020$1.01M
    Dec 31, 2019-$4.61-$4.59-$4.80 - -$4.48-0.44%MissN/A3N/AMar 12, 2020$1.52M
    Sep 30, 2019-$4.80-$4.95-$5.11 - -$4.50+3.03%BeatN/A3N/ANov 12, 2019$606619
    Jun 30, 2019-$4.50-$5.10N/A+11.76%BeatN/A2N/AAug 8, 2019$880349
    Mar 31, 2019-$5.10-$6.00N/A+15.00%BeatN/A1N/AMay 13, 2019$830066
    Dec 31, 2018-$6.51-$7.50N/A+13.20%BeatN/A1N/AMar 7, 2019$889575
    Sep 30, 2018-$6.43-$6.90N/A+6.81%BeatN/A1N/ANov 5, 2018$608981
    Jun 30, 2018-$6.36-$5.40-$6.01 - -$5.11-17.78%MissN/A2N/AAug 7, 2018$632369
    Mar 31, 2018-$5.95-$5.70-$5.71 - -$5.41-4.39%MissN/A2N/AMay 9, 2018$313179
    Dec 31, 2017-$7.20-$9.90N/A+27.27%BeatN/A1N/AMar 7, 2018$547412
    Sep 30, 2017-$6.30-$9.00N/A+30.00%BeatN/AN/AN/ANov 6, 2017$488540
    Jun 30, 2017-$0.24N/AN/AN/AN/AN/AN/AN/AAug 14, 2017$306683
    Last 38 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.37, after -$0.17 the year before. It was -$13.74 for the year ended Dec 31, 2017, the oldest of the 9 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.37N/A
    Dec 31, 2024-$0.17N/A
    Dec 31, 2023-$0.28N/A
    Dec 31, 2022-$1.52N/A
    Dec 31, 2021-$1.91N/A
    Dec 31, 2020-$4.52N/A
    Dec 31, 2019-$19.01N/A
    Dec 31, 2018-$25.25N/A
    Dec 31, 2017-$13.74N/A

    Earnings Calls

    The 6 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 4,700 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20264,6907
    2025Q3Sep 30, 20255,6589
    2025Q2Jun 30, 20256,7209
    2025Q1Mar 31, 20256,3379
    2024Q3Sep 30, 20245,7489
    2024Q2Jun 30, 20245,1919

    2026Q1 Earnings Call

    Opening remarks

    Bruce Voss Investor Relations Thank you and good afternoon, everybody. This is Bruce Voss with Alliance Advisors IR. Welcome to the Myomo, Inc. First Quarter 2026 Financial Results Conference Call. With me on today's call are Myomo, Inc.'s Chief Executive Officer, Paul R. Gudonis, and Chief Financial Officer, David A. Henry. Before we begin, I would like to caution listeners that statements made during this call by management other than historical facts are forward-looking statements. The words anticipate, believe, estimate, expect, intend, guidance, outlook, confidence, target, project and other similar expressions are typically used to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to risks, uncertainties and other factors that may affect Myomo, Inc.'s business, financial condition and operating results. These risks, uncertainties and other factors are discussed in Myomo, Inc.'s filings with the Securities and Exchange Commission. Actual outcomes and results may differ materially from what is expressed in or implied by these forward-looking statements. Furthermore, except as required by law, Myomo, Inc. undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this call today, 05/07/2026. Now it is my pleasure to turn the call over to Myomo, Inc.'s CEO, Paul. Paul, please go ahead.

    Paul R. Gudonis Chief Executive Officer Thanks, Bruce. Well, good afternoon, and thank you all for joining us today. We remain very excited about the opportunity in front of us to improve lives and grow our company. Chronic upper-limb paralysis is an underserved medical condition and each year stroke leaves hundreds of thousands of Americans with long-lasting arm impairments. When you add in spinal cord injury, traumatic brain injury and brachial plexus injuries, the addressable U.S. population reaches into the millions, and globally millions more. For most of these patients, the standard of care has been a passive brace, ongoing physical therapy with diminishing returns, or resignation to permanent loss of function. Our MyoPro is the only commercially available powered arm orthosis in the U.S. that uses non-invasive EMG sensors to detect the patient's own muscle signals and amplify them into functional movement, thereby permitting paralyzed individuals to feed themselves, carry objects, return to work, and reclaim independence at home. It is not an incremental improvement on existing care. It is really an entirely different category of device and Myomo, Inc. owns it. Let me start with a quick real-life story.

    Frequently Asked Questions About MYO

    When is Myomo's next earnings date?

    Myomo's next earnings report is confirmed for Mar 8, 2027, after the close.

    Did MYO beat earnings estimates last quarter?

    Yes. Myomo reported EPS of -$0.07 for the quarter ended Sep 30, 2026, above the -$0.08 estimate, a 12.50% surprise.

    What EPS do analysts expect from MYO next quarter?

    The consensus EPS estimate for Myomo for the quarter ending Dec 31, 2026 is -$0.07 from 6 analysts, with estimates from -$0.08 to -$0.06.

    How often does MYO beat earnings estimates?

    Myomo beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +16.81%.

    Does MYO report before or after the market opens?

    Myomo is confirmed to report on Mar 8, 2027, after the market closes.